Osteopen vet.
Active substance
ATC code
Species
Dogs.
Indications
For the treatment of lameness and pain of degenerative joint disease/osteoarthritis (noninfectious arthrosis) in the skeletally mature dog.
Dose to be administered and administration route
3 mg pentosan polysulphate sodium / kg bodyweight (equivalent to 0.3 ml/10kg bodyweight) on four occasions, with an interval of 5-7 days.
Administer by aseptic subcutaneous injection only. An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes.
To establish the appropriate dosage, the weight of the individual animal should be determined prior to administering the veterinary medicinal product.
Adverse reactions
Rarely, reaction to the injection may occur within 24 hours in an apparently healthy animal. In these circumstances treatment should be discontinued and symptomatic relief given.
Experience indicates that in very rare cases, dogs may vomit immediately after injection with pentosan polysulphate.
Such dogs generally require no medical treatment and make an uneventful recovery.
Further treatment with pentosan polysulphate is not recommended.
A further very rare side effect following administration of pentosan polysulphate sodium in dogs is an apparent mild depression and lethargy lasting up to 24 hours.
Emesis, diarrhoea, lethargy and anorexia have been reported following the use of pentosan polysulphate. These signs may be the result of a hypersensitivity reaction and may require appropriate symptomatic treatment including antihistamine administration. Administration of the product at recommended dose rates results in increases of activated partial thromboplastin time (aPTT) and thrombin time (TT) which may persist for up to 24 hours after administration in healthy dogs. This very rarely results in clinical effects, but because of the fibrinolytic action of pentosan polysulphate sodium, the possibility of internal bleeding from a tumour or vascular abnormality should be considered if signs develop. It is recommended that the animal should be monitored for signs of blood loss and treated appropriately
Bleeding disorders such as nasal bleeding, haemorrhagic diarrhoea and haematomas have been reported.
Local reactions such as a transient swelling have been observed post injection.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 08749/4086 |
Similar products
Showing 1 of 1 results
